Invasive Brain–Computer Interfaces: Advancements, Challenges, and Societal Considerations

Preet Rathore [1], Jitraj Esh [2]

Department of Computer Science
Kristu Jayanti (Deemed To be University)

Abstract

Invasive brain–computer interfaces (BCIs) record neural signals directly from the cortex, offering high-resolution control signals for digital devices. Neuralink's "Telepathy" N1 system exemplifies this approach, using thousands of fine electrode threads implanted with a robotic inserter. Since its FDA approval for human trials, Neuralink has reported initial success in enabling a paralyzed patient to control a computer by thought. This report examines Neuralink's technology custom ASICs, flexible polymer threads, and surgical robot alongside other invasive BCI platforms such as Blackrock's Utah array, Synchron's Stentrode, and Paradromics' Connexus. Key challenges include neural tissue reactions (gliosis) that degrade signal quality over time, device durability, and safe chronic implantation. We review the system's current clinical status, potential medical applications such as restoring communication and motor function, and advantages over non-invasive EEG, notably higher signal fidelity. Ethical, regulatory, and societal issues are also considered, including public sentiment, privacy, and safety standards for neural data.

Introduction

Brain–computer interfaces (BCIs) are systems that translate neural activity into commands for external devices. Non-invasive BCIs, such as EEG, record scalp potentials, whereas invasive BCIs use surgically implanted electrodes for direct brain access. Invasive approaches capture single-neuron spikes with much higher spatial and temporal resolution, enabling more precise decoding of intent. Neuralink, founded in 2016 by Elon Musk, aims to leverage this high-fidelity signal to restore communication and control to individuals with paralysis. Its "Telepathy" N1 implant is designed as a fully implanted wireless system to record from many thousands of neurons simultaneously. Neuralink's public demonstrations and first-in-human implantation have drawn wide media attention. This report uses Neuralink as a case study to explore invasive BCI technology, covering implant design and surgical procedure, clinical progress, applications, technical and regulatory challenges, and ethical considerations. We compare Neuralink to other invasive BCI systems and discuss societal impacts.

Implant Design and Surgical Procedure

Neuralink's invasive brain–computer interface centers on a fully implantable neural recording system designed to achieve high channel density while minimizing physical burden on the user. The implant, commonly referred to as the "Link," is a compact, diskshaped module constructed from biocompatible titanium. It integrates signal acquisition electronics, power storage, and wireless communication within a sealed enclosure intended for long-term intracranial placement. To protect internal components from moisture and corrosion, the housing is hermetically sealed and further insulated with biocompatible coatings such as parylene-C.

Neural signals are captured through an array of flexible polymer-based electrode threads that extend from the implant into cortical tissue. These threads are significantly thinner than conventional rigid electrodes and are designed to conform to natural brain motion, thereby reducing mechanical strain at the tissue–electrode interface. Each thread carries multiple microelectrodes, allowing the system to record activity from large populations of neurons simultaneously. Custom low-power integrated circuits embedded within the implant amplify and digitize these signals, enabling high temporal resolution recordings while limiting heat generation and power consumption.

Placement of the electrode threads is performed using a specialized robotic surgical system engineered for micron-scale precision. The robot assists in identifying optimal insertion sites while avoiding surface vasculature, thereby reducing the likelihood of hemorrhage during implantation. Automated insertion allows multiple threads to be deployed efficiently within a short surgical window. Following electrode placement, the implant is secured within the skull, and the dura and scalp are closed

Current Clinical Status and Progress

Neuralink's research trajectory has moved from extensive preclinical experimentation toward early-stage human evaluation. After initial regulatory hesitation, the U.S. Food and Drug Administration authorized the company to begin first-in-human testing, marking a significant milestone in the development of high-channel-count invasive brain–computer interfaces. This approval permitted limited clinical investigation under strict safety and monitoring requirements.

In early 2024, Neuralink reported the implantation of its Telepathy N1 system in an individual with quadriplegia. According to company disclosures, the participant demonstrated the ability to interact with a computer interface by translating neural activity into cursor movement and simple digital commands. These early demonstrations suggest that intracortical recordings can support functional device control without physical movement. However, reported performance remains preliminary and has not yet been independently validated through peer-reviewed clinical publications.

Subsequent updates from Neuralink indicated technical challenges during early use, including partial degradation of recorded signals. These issues were attributed to movement-related changes at the brain–implant interface, which can cause implanted electrodes to shift relative to neural tissue over time. Such observations highlight persistent difficulties associated with chronic implantation, particularly in maintaining long-term signal stability.

In parallel with human testing, Neuralink has released results from animal studies demonstrating sustained neural recordings across large electrode arrays. These preclinical findings support the feasibility of high-density recording architectures but do not fully resolve questions related to long-term human safety, durability, or functional benefit. Experts in the field emphasize that broader clinical trials, standardized outcome measures, and longer follow-up periods are necessary before definitive conclusions regarding efficacy can be drawn.

Medical Applications of Invasive BCIs

The primary motivation for Neuralink and similar systems is medical rehabilitation. For individuals with severe paralysis, invasive BCIs offer a means to restore communication and control. By decoding intended movements or speech from motor cortex activity, patients can operate computers, prosthetic limbs, or speech synthesizers using thought alone. Clinical trials with other invasive BCIs have demonstrated that patients can perform daily tasks such as texting, shopping, and banking independently.

Beyond motor and speech restoration, invasive BCIs may enable therapies for neurological disorders. Targeted neural stimulation could support treatment of conditions such as Parkinson’s disease, epilepsy, or depression. Neuralink has also proposed future applications such as visual cortex implants for restoring vision or potential cognitive enhancement, although these remain speculative.

Compared with non-invasive systems, invasive BCIs enable finer granularity of control. Signals recorded directly from the cortex capture activity from individual neurons or small neural ensembles, unlike EEG which measures broad scalp potentials. This allows more complex commands and higher communication bandwidth, potentially enabling faster and more natural prosthetic control or speech synthesis.

Advantages of Invasive BCIs over Non-Invasive Methods

Invasive implants offer higher signal fidelity and signal-to-noise ratio because electrodes are placed directly on or within brain tissue. Whereas EEG captures low-frequency averaged signals, intracortical electrodes can isolate action potentials from individual neurons. This enables faster and more precise decoding of neural intent, with high spatial and temporal resolution.

Invasive BCIs also offer greater control bandwidth. With hundreds or thousands of electrodes, these systems can access large neural populations, supporting simultaneous control of multiple degrees of freedom. Clinical trials using intracortical arrays have demonstrated two-dimensional cursor control and three-dimensional robotic limb movement, and higher channel counts may further improve performance.

From a usability perspective, fully implanted wireless designs improve comfort and practicality. Neuralink’s system avoids external headgear or wired tethers, allowing continuous use after surgical recovery. Inductive charging and biocompatible coatings support long-term implantation without repeated surgical intervention.

These advantages come with trade-offs. Invasive surgery carries inherent risks, and implanted arrays may degrade over time. Non-invasive methods remain safer and more accessible, making invasive BCIs most appropriate for patients with severe disabilities who have limited alternatives.

Comparison with Other Invasive BCI Technologies

Neuralink's system represents one of several distinct design philosophies within the landscape of invasive brain–computer interfaces. While all such systems aim to record neural activity with high fidelity, they differ substantially in electrode architecture, implantation strategy, and clinical objectives.

One of the most established platforms is Blackrock Neurotech's Utah array, which has been widely employed in academic and clinical research for over a decade. This rigid, needle-based array enables stable intracortical recordings and has supported early demonstrations of motor decoding and cursor control. However, its relatively low channel count and reliance on percutaneous connectors limit long-term usability and increase infection risk, restricting its application largely to controlled research environments.

Paradromics has introduced an alternative approach through its Connexus interface, which prioritizes high data throughput and speech decoding. This system employs fine microwire electrodes connected to a subcutaneous implant, separating the recording interface from the cranial site. By relocating processing hardware away from the skull, the design seeks to improve durability and reduce surgical constraints. Early regulatory approvals suggest potential for clinical translation, although human efficacy data remain forthcoming.

Synchron's Stentrode device follows a markedly different strategy by avoiding open-brain surgery altogether. Delivered endovascularly via blood vessels, the Stentrode records neural signals from within the vasculature adjacent to motor cortex. This minimally invasive method significantly reduces surgical risk and has demonstrated stable long-term performance in human trials. However, because it records electrocorticographic rather than intracortical signals, its spatial resolution and decoding precision are inherently lower than those of penetrating electrode systems.

In comparison, Neuralink's approach emphasizes ultra-high channel density combined with a fully implanted, wireless architecture. Its use of flexible polymer threads seeks to balance signal quality with reduced tissue damage, positioning the system between traditional rigid arrays and minimally invasive vascular devices. Each platform reflects trade-offs among invasiveness, signal resolution, scalability, and regulatory complexity, underscoring that no single design currently satisfies all clinical and practical requirements.

Technical Challenges and Engineering Solutions

Despite rapid progress, significant challenges remain. Implanted electrodes can trigger immune responses, leading to glial scarring that degrades signal quality over time. Neuralink's flexible polymer threads are designed to move with brain tissue, reducing damage, but their flexibility complicates insertion and long-term stability.

Device packaging and power management are also critical challenges. Fully implantable systems must balance size, heat dissipation, and battery life while maintaining hermetic sealing. Wireless data transfer must achieve high bandwidth with minimal power consumption to avoid tissue heating.

Signal processing and decoding present additional hurdles. Large-scale neural recordings require advanced algorithms to extract meaningful intent in real time. Adaptive machine-learning decoders are being developed to compensate for signal drift and improve performance as users gain experience.

Regulatory and manufacturing considerations further complicate development. Scaling production while meeting stringent medical device standards requires automated fabrication and extensive testing. Regulatory approvals limit early deployment to controlled trials, emphasizing safety and reliability.

Public Perception and Media Influence

Brain–computer interfaces have captured public imagination, driven by media coverage and high-profile figures. Public sentiment is mixed, combining excitement about medical potential with concern over safety, privacy, and ethical implications. Media narratives often amplify both optimism and fear, sometimes obscuring technical realities.

High-profile announcements, such as Neuralink's first human implantation, have attracted global attention. While many view these developments as scientific milestones, others express skepticism about risks, animal welfare, and corporate motives. Transparent communication and peer-reviewed evidence are essential for building public trust.

Legal and Regulatory Frameworks

Invasive BCIs occupy a complex regulatory landscape at the intersection of medical devices, data protection, and neuroethics. Regulatory agencies have issued guidance for implantable BCIs, outlining requirements for preclinical testing and clinical trials. Investigational pathways allow limited human testing while comprehensive safety data are gathered.

However, no unified legal framework yet governs neurotechnology. Existing medical device laws address physical safety, but neural data raise unique privacy concerns. Neural signals may reveal sensitive information about thoughts or intentions, and current data protection laws do not explicitly address this category. International organizations have begun developing ethical guidelines to safeguard mental privacy and autonomy.

Risks and Ethical Concerns

Invasive BCIs involve surgical risks, including hemorrhage, infection, and neural damage. Long-term risks include inflammation, device failure, and the need for revision surgery. Ethical concerns center on privacy, consent, and autonomy. Neural data are uniquely personal, and questions remain about data ownership and control.

There are also concerns about identity and long-term responsibility. Patients may depend on implanted devices for communication or control, raising questions about continuity of care if companies discontinue support. Equity and access further complicate ethical evaluation, as advanced neurotechnologies may be available only to limited populations.

Future Outlook

The field of invasive BCIs is advancing rapidly, driven by increased investment and technological innovation. Improvements in materials, electronics, and decoding algorithms are expected to enhance performance and safety. Regulatory frameworks and ethical guidelines are likely to evolve alongside these advances.

Despite progress, long-term safety and societal acceptance remain uncertain. Demonstrating clear patient benefit, maintaining transparency, and addressing ethical concerns will be essential. Ultimately, the goal of restoring function and independence to individuals with severe disabilities continues to motivate research and development in invasive brain–computer interfaces.

References

- Almanna, M. A., Elkaim, L. M., Alvi, M. A., Levett, J. J., Li, B., Alquraishi, H., et al. (2025). *Public perception of the Brain-Computer Interface based on a decade of data on X: Mixed methods study*. JMIR Formative Research, 9, e60859.
- Ortega-Robles, E., García-Medrano, C. C., Camacho-Pérez, L. I., & Cavazos-Cadenas, J. (2023). *Brain–computer interfaces in Parkinson’s disease rehabilitation*. Applied Sciences, 13(12), 6925.
- Lavazza, A., Balconi, M., Ienca, M., Minerva, F., Pizzetti, F. G., Reichlin, M., Samorè, F., Sironi, V. A., Sosa Navarro, M., & Songhorian, S. (2025). Neuralink’s brain-computer interfaces: Medical innovations and ethical challenges. *Frontiers in Human Dynamics*, 7, 1553905.
- Musk, E. J., Musk, T. K., & Neuralink (2019). An integrated brain-machine interface platform with thousands of channels. *Journal of Medical Internet Research*, 21(10), e16194.

- Mullin, E. (2024, May 9). Elon Musk's Neuralink had a brain implant setback. It may come down to design. *Wired*. https://www.wired.com/story/neuralink-brain-implant-setback/
- Oxley, T. J., Yoo, P. E., Rind, G. S., Ronayne, S. M., Lee, C. S., Bird, C., et al. (2021). Motor neuroprosthesis implanted with neurointerventional surgery improves capacity for activities of daily living tasks in severe paralysis: First-in-human experience. *Journal of NeuroInterventional Surgery*, 13(2), 102–108.
- Paradromics, Inc. (2025, November 20). *Paradromics receives FDA approval for the Connect-One clinical study with the Connexus® brain-computer interface*. (Press release). https://www.paradromics.com/news/paradromics-receives-fda-approval-for-the-connect-one-clinical-study-with-the-connexus-brain-computer-interface
- Reuters Staff (2023, May 26). *Elon Musk's Neuralink wins FDA approval for human study of brain implants*. Reuters. https://www.reuters.com/science/elon-musks-neuralink-gets-us-fda-approval-human-clinical-study-brain-implants-2023-05-25/
- UNESCO (2025, November 5). *Ethics of neurotechnology: UNESCO adopts the first global standard in cutting-edge technology* [Press release]. https://www.unesco.org/en/articles/ethics-neurotechnology-unesco-adopts-first-global-standard-cutting-edge-technology
- Yang, H., & Jiang, L. (2025). Regulating neural data processing in the age of BCIs: Ethical concerns and legal approaches. *Digital Health*, 11, 20552076251326123. DOI: 10.1177/20552076251326123.
- Egger-Robles, E., García-Medrano, C. C., Camacho-Pérez, L. I., & Cavazos-Cadenas, J. (2023). Brain–Computer Interfaces in Parkinson's Disease Rehabilitation. *Applied Sciences*, 13(12), 6925.

Elon Musk's Neuralink wins FDA approval for human study of brain implants | Reuters

https://www.reuters.com/science/elon-musks-neuralink-gets-us-fda-approval-human-clinical-study-brain-implants-2023-05-25/

Frontiers | Neuralink's brain-computer interfaces: medical innovations and ethical challenges

https://www.frontiersin.org/journals/human-dynamics/articles/10.3389/fhumd.2025.1553905/full

Journal of Medical Internet Research - An Integrated Brain-Machine Interface Platform With Thousands of Channels

http://www.jmir.org/2019/10/e16194/

Elon Musk's Neuralink Had a Brain Implant Setback. It May Come Down to Design | WIRED https://www.wired.com/story/neuralinks-brain-implant-issues/?_sp=7ce26169-909b-486f-ac82-6aa4781bd73a.1715286609559&redirectURL=https%3A%2F%2Fwww.wired.com%2Fstory%2Fneuralinks-brain-implant-issues%2F%3F_sp%3D7ce26169-909b-486f-ac82-6aa4781bd73a.1715286609559

Motor neuroprosthesis implanted with neurointerventional surgery improves capacity for activities of daily living tasks in severe paralysis: first in-human experience - PubMed

https://pubmed.ncbi.nlm.nih.gov/33115813/

Brain–Computer Interfaces in Parkinson’s Disease Rehabilitation - PMC

https://pmc.ncbi.nlm.nih.gov/articles/PMC12383679/

Public Perception of the Brain-Computer Interface Based on a Decade of Data on X: Mixed Methods Study - PMC

https://pmc.ncbi.nlm.nih.gov/articles/PMC12242710/

Regulating neural data processing in the age of BCIs: Ethical concerns and legal approaches - PMC

https://pmc.ncbi.nlm.nih.gov/articles/PMC11951885/

Paradromics Receives FDA Approval for the Connect-One Clinical Study with the Connexus® Brain-Computer Interface

https://www.paradromics.com/news/paradromics-receives-fda-approval-for-the-connect-one-clinical-study-with-the-connexus-brain-computer-interface

Paradromics BCI trial to restore speech gets FDA approval

https://newatlas.com/medical-devices/human-trial-experimental-brain-chip-connexus/

Healthtech and the FDA | Fueling collaborative regulation in neurotechnology

https://www.paradromics.com/blog/healthtech-advanced-by-fda

Ethics of neurotechnology: UNESCO adopts the first global standard in

https://www.unesco.org/en/articles/ethics-neurotechnology-unesco-adopts-first-global-standard-cutting-edge-technology